Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
EBioMedicine
; 93: 104662, 2023 Jul.
Article
in En
| MEDLINE
| ID: mdl-37354600
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Chronic Progressive
/
Multiple Sclerosis, Relapsing-Remitting
/
Multiple Sclerosis
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
EBioMedicine
Year:
2023
Type:
Article